The European Union Has Approved AstraZeneca's Imfinzi (Durvalumab) And Lynparza (Olaparib) Have Been Approved For Certain Patients With Primary Advanced Or Recurrent Endometrial Cancer
Author: Benzinga Newsdesk | August 14, 2024 05:42am
Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease.
Imfinzi plus chemotherapy followed by Imfinzi alone has been approved for patients with mismatch repair deficient (dMMR) disease.